|IRONWOOD PHARMACEUTICALS INC (IRWD)
|Original Submission Date:
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300 BOSTON, MA 02110
|Title of Security
|2a. Deemed Execution Date
|Acquired or Disposed
|Price per share
|5. Amount of Securities Beneficially Owned Following Reported Transaction
|6. Ownership Form Direct or Indirect
|Nature of Indirect Ownership
|CLASS A COMMON STOCK
|Title of Derivative Security
|Conversion or Exercise Price of Derivative Security
|Deemed Execution Date
|Number of Derivative Securities Acquired (A) or Disposed of (D)
|Title and Amount of Securities Underlying Derivative Security
|Price of Derivative Security
|Number of derivative Securities Beneficially Owned Following Reported Transaction(s)
|Ownership Form: Direct (D) or Indirect (I)
|Nature of Indirect Beneficial Ownership
|the sale reported on this form 4 represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. the sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
|the reporting person acquired 1,334 shares of class a common stock under the issuer's employee stock purchase plan on june 30, 2023.